Potent and selective second-generation phosphodiesterase type 5 (PDE5) inhibitor

Novel G6PD inhibitor

Novel inducer of mitotic arrest and apoptosis in human progenitor and cancer cells

Novel selective inhibitor of STAT3 phosphorylation, binding to the SH2 domain of STAT3, exhibiting remarkable antiproliferative activity against three cancer cell lines (HCT-116, SW480 and MDA-MB-231)

Novel cell specific photoswitchable agonist for reversible control of endogenous dopamine receptors

Novel, potent, and selective NR1/2B NMDA receptor antagonist

AMPA receptor antagonist

AMPA receptor antagonist

Neuropeptide Y Y1 receptor antagonist

Selective antagonist for human ETA receptors

Selective D3 dopamine receptor agonist

Novel potent programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitor (IC50 9.1 nM)

Novel inhibitor of PD-1/PD-L1 (IC 50 value of 56.58 nM), dose-dependently promoting HepG2 cell death in a co-culture model of HepG2/hPD-L1 and Jurkat T cells, effectively inhibiting tumor growth (TGI of 76.4% at 90 mg/kg) in an immune checkpoint humanized

Novel Potent Inhibitor of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction

Novel bifunctional inhibitor of PD-1/PD-L1 interactions, promoting dimerization, internalization, and degradation of PD-L1, suppressing tumor growth in vivo by activating antitumor immunity

Novel potent PD-1/PD-L1 antagonist (IC50 of 16.17 nM), activating the antitumor immunity of T cells efficiently in PBMCs

Novel inhibitor of PD-I/PD-L1 interaction to be used as a negative immune checkpoint regulatory and antineoplastic agent

Novel liver-targeted inhibitor of ribosomal synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9)

Novel PCSK9 mRNA translation inhibitor

Novel PCSK9 mRNA translation inhibitor

Novel modulator of proprotein convertase subtilisin kexin like type 9 (PCSK9)

Novel potent dopamine D3R antagonist

Novel potent and selective dopamine D3R partial agonist

Novel potent dopamine D3R agonist (Ki=4.1nM)

Highly selective α1L adrenaline receptor agonist

Potent antagonist of the series disrupting EphA2-ephrinA1 interaction, blocking EphA2 phosphorylation in prostate cancer cells at low

Organoselenium compound with antidepressant-like and memory enhancer actions

Novel α7 nAChR weak partial agonist, showing antinociceptive and anti-inflammatory properties

Novel activator of effector T cells, enhancing T cell proliferation and activation to release interferon gamma (IFN-γ) and interleukin-2 (IL-2) without blocking the programmed cell death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) binding and not dire

Novel Chelator for Cu-64